



The Promise of Induced Pluripotent Stem Cells in the Biomedical Research 2.0

Guest Editor:

Dr. M. Esther Gallardo

Head of Translational Research
with iPS Cells Group, Research
Institute Hospital 12 de Octubre,
i+12, Madrid, Spain

Deadline for manuscript
submissions:

closed (30 April 2023)

Message from the Guest Editor

Dear Colleagues,

More than a decade ago, the Japanese scientist Shinya Yamanaka showed that it is possible to convert adult cells into a state similar to that of pluripotent stem cell. These cells, named induced pluripotent stem cells (iPSCs), are similar to embryonic stem cells (ES) and are considered a very promising tool in the field of regenerative medicine. iPSCs, like ES cells, are self-renewing and pluripotent. Furthermore, because iPSCs are obtained from adult cells in vitro, they do not raise the ethical and legal problems associated with the use of ES cells. Because they are generated from the patient, the likelihood of rejection in autologous therapies is believed to be much lower. This Special Issue will address the applications of iPSCs, putting a special emphasis on the investigation of the physiopathogenic mechanisms behind diseases and the search for new therapies against them. Therefore, contributions by experts in the field, in the form of original articles and reviews, are most welcome.

- induced pluripotent stem cells
- drug discovery
- cell modelling
- cell therapy
- personalized medicine
- tissue engineering





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI